Trade Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development and marketing of therapeutic RNA intervention (RNAi) for genetically modified diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes listed the company as "top 100 innovative growth companies." in 2002, Alnylam was founded by scientists Philip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Philip Zamur, and investors Christoph Westphal and John F. Kennedy Clark; John Marragan was the founding CEO. The company is named after The Nileam, a star in the Orion belt. The spelling has been modified to make it unique. In 2003, the company merged with German pharmaceutical company Repopharma AG. The newly formed company also received $24.6 million in funding from private equity firms. On February 27, 2004, Alnylam Pharmaceuticals applied for an initial public offering. The company raised $26 million and started trading as ALNY on nasdaq. In 2005, the company partnered with Medtronik to develop drug body formulations for the treatment of neurodegenerative disorders, and in 2006 with Biogen Idec to develop progressive multifocal thrombosis treatments. In 2007, it entered into a non-comprehensive alliance with Hoffman-LaRoche, where Alnylam received $331 million in access to its technology platform. It has also partnered with Isis Pharmaceuticals to establish Regulus Therapeutics, which focuses on microrna treatments. In 2009, the company formed alliances with Cubist Pharmaceuticals and Kiwa Haku Kirin to market a drug targeting a synchronous respiratory virus. In 2010, it expanded its previous collaboration with Medtronics to include CHDI in her research focusing on Huntington's disease. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology that promotes vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotechnology solutions for the agriculture industry by developing natural molecules to protect crops. In 2012, she formed a partnership with Sanofi Genzim to develop a treatment for amyloidosis with tertirein, a hereditary disease in Asia. In February 2013, it formed a partnership with the pharmaceutical company to develop a drug to treat a genetic form of high cholesterol. In July 2013, during the trial of The First Phase Alnylam showed a statistically significant decrease in a protein called Transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous methods of administration. In 2014, Sanofi Genzim acquired a 12 percent stake in Nileam and increased its rights to several of the company's drugs for $700 million. In a separate deal, Alnylam announced that it had bought Serna Trapi from Merck & Co., for $25 million in cash and $150 million in shares. In 2015, the company generated $41 million in revenue and a market cap of $5.2 billion. In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility. In October 2016, the clinical trial of the third phase of the company's main product, revusiran, was discontinued due to increased mortality in the drug arm for the trial, and the company said it was finalizing the development of the complex. In February 2020, Anialam appointed former Sanofi CEO Olivier Brandicourt to its board of directors.